|
|
Volumn 65, Issue 2, 2016, Pages 446-448
|
|
High mortality during direct acting antiviral therapy for hepatitis C patients with Child's C cirrhosis: Results of the Irish Early Access Programme
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALBUMIN;
BILIRUBIN;
LEDIPASVIR PLUS SOFOSBUVIR;
RIBAVIRIN;
ANTIVIRUS AGENT;
ADULT;
AGED;
ALBUMIN BLOOD LEVEL;
ANTIVIRAL THERAPY;
BILIRUBIN BLOOD LEVEL;
BRAIN HEMORRHAGE;
CHILD PUGH SCORE;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG WITHDRAWAL;
FEMALE;
HEART ARREST;
HEPATITIS C;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
IRELAND;
LETTER;
LIVER CELL CARCINOMA;
LIVER CIRRHOSIS;
LIVER FAILURE;
LONGITUDINAL STUDY;
MAJOR CLINICAL STUDY;
MALE;
MEDICATION COMPLIANCE;
MIXED INFECTION;
MODEL FOR END STAGE LIVER DISEASE SCORE;
MORTALITY;
MORTALITY RATE;
PATIENT COMPLIANCE;
PREVALENCE;
PRIORITY JOURNAL;
PROSPECTIVE STUDY;
SEPSIS;
THROMBOCYTE COUNT;
TREATMENT DURATION;
TREATMENT OUTCOME;
TREATMENT RESPONSE;
CHILD;
HEPACIVIRUS;
ANTIVIRAL AGENTS;
CHILD;
HEPACIVIRUS;
HEPATITIS C;
HUMANS;
LIVER CIRRHOSIS;
|
|
EID: 84969964439
PISSN: 01688278
EISSN: 16000641
Source Type: Journal
DOI: 10.1016/j.jhep.2016.03.022 Document Type: Letter |
|
Times cited : (11)
|
|
References (2)
|
